Integrated bioassays in microfluidic devices: Botulinum toxin assays

21Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

A microfluidic assay was developed for screening botulinum neurotoxin serotype A (BoNT-A) by using a fluorescent resonance energy transfer (FRET) assay. Molded silicone microdevices with integral valves, pumps, and reagent reservoirs were designed and fabricated. 1-4 Electrical and pneumatic control hardware were constructed, and software was written to automate the assay protocol and data acquisition. Detection was accomplished by fluorescence microscopy. The system was validated with a peptide inhibitor, running 2 parallel assays, as a feasibility demonstration. The small footprint of each bioreactor cell (0.5 cm2) and scalable fluidic architecture enabled many parallel assays on a single chip. The chip is programmable to run a dilution series in each lane, generating concentration-response data for multiple inhibitors. The assay results showed good agreement with the corresponding experiments done at a macroscale level. Although the system has been developed for BoNT-A screening, a wide variety of assays can be performed on the microfluidic chip with little or no modification. © 2005 The Society for Biomolecular Screening.

Cite

CITATION STYLE

APA

Mangru, S., Bentz, B. L., Davis, T. J., Desai, N., Stabile, P. J., Schmidt, J. J., … Kodukula, K. (2005). Integrated bioassays in microfluidic devices: Botulinum toxin assays. Journal of Biomolecular Screening, 10(8), 788–794. https://doi.org/10.1177/1087057105278927

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free